Recro Pharma Inc (NASDAQ:REPH) CEO Geraldine Henwood sold 144,806 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $8.89, for a total value of $1,287,325.34. Following the completion of the sale, the chief executive officer now owns 342,947 shares of the company’s stock, valued at approximately $3,048,798.83. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Recro Pharma stock traded up $0.53 during midday trading on Wednesday, reaching $9.40. 345,584 shares of the company’s stock traded hands, compared to its average volume of 366,498. The company has a quick ratio of 2.08, a current ratio of 3.56 and a debt-to-equity ratio of 4.04. The company has a market cap of $201.17 million, a PE ratio of -3.81 and a beta of -0.13. Recro Pharma Inc has a 12 month low of $4.78 and a 12 month high of $13.05.
Recro Pharma (NASDAQ:REPH) last announced its earnings results on Friday, May 10th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.69. The company had revenue of $25.07 million during the quarter, compared to the consensus estimate of $20.51 million. Recro Pharma had a negative return on equity of 654.93% and a negative net margin of 83.56%. On average, research analysts anticipate that Recro Pharma Inc will post -1.94 earnings per share for the current year.
Several analysts have weighed in on the company. ValuEngine downgraded Recro Pharma from a “buy” rating to a “hold” rating in a research report on Monday. Zacks Investment Research downgraded Recro Pharma from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 23rd. Roth Capital reiterated a “neutral” rating and issued a $7.50 price objective (down previously from $15.00) on shares of Recro Pharma in a research report on Monday, March 25th. Janney Montgomery Scott reiterated a “buy” rating and issued a $13.00 price objective on shares of Recro Pharma in a research report on Thursday, January 31st. Finally, Oppenheimer upped their target price on Recro Pharma from $9.00 to $15.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Recro Pharma has a consensus rating of “Buy” and an average target price of $10.95.
A number of institutional investors and hedge funds have recently bought and sold shares of REPH. Meeder Asset Management Inc. raised its holdings in Recro Pharma by 191.1% in the first quarter. Meeder Asset Management Inc. now owns 5,086 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 3,339 shares in the last quarter. Truvestments Capital LLC bought a new position in Recro Pharma in the first quarter worth $38,000. Virtu Financial LLC raised its holdings in Recro Pharma by 27.7% in the first quarter. Virtu Financial LLC now owns 12,875 shares of the specialty pharmaceutical company’s stock worth $75,000 after purchasing an additional 2,795 shares in the last quarter. State of Wisconsin Investment Board raised its holdings in Recro Pharma by 29.5% in the first quarter. State of Wisconsin Investment Board now owns 23,700 shares of the specialty pharmaceutical company’s stock worth $139,000 after purchasing an additional 5,400 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in Recro Pharma by 47.8% in the fourth quarter. Rhumbline Advisers now owns 23,753 shares of the specialty pharmaceutical company’s stock worth $169,000 after purchasing an additional 7,679 shares in the last quarter. Institutional investors and hedge funds own 56.12% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2019/05/15/recro-pharma-inc-reph-ceo-geraldine-henwood-sells-144806-shares.html.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Read More: Intrinsic Value
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.